BERLIN, October 2, 2018 /PRNewswire/ -- According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved glycaemic control (HbA1c) with Tresiba® (insulin degludec) versus insulin glargine U100, without an increase in...
from PR Newswire: //https://ift.tt/2Iw78jE
No comments:
Post a Comment